Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Gossamer Bio's seralutinib shows promise in PAH Phase 2 trials, but Phase 3 success is vital amidst competition. Click to ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

At Santi, Michael White shows once more that he is among the city’s most talented makers of la cucina Italiana.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

There’s a very specific thrill in swapping out your clunky old rucksack for a sleek, streamlined fastpack that seems to disappear once you put it on, and that’s exactly what Gossamer Gear ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

Gossamer Bio (NASDAQ:GOSS – Free Report) had its target price cut by The Goldman Sachs Group from $8.00 to $7.00 in a research report sent to investors on Thursday,Benzinga reports.They ...

In this article, we are going to take a look at where Gossamer Bio Inc. (NASDAQ:GOSS) stands against other penny stocks to invest in under $1. Earlier on February 12 this year, Chief Investment ...